BTIG analyst Sean Lavin upgraded Varian Medical to Buy from Neutral with a $130 price target. Varian shares have pulled back in recent weeks and now trade in line with the comp group, Lavin tells investors in a research note. The analyst, however, thinks the company deserves to trade at a small premium to the group since it growing both revenue and earnings faster than its peers. Further, Varian Medical has an "enviable market leading position," and is shifting its business toward faster growing, higher margin areas such as software and single-use devices, contends the analyst. He views the stock pullback as an opportunity to upgrade the shares to Buy.